San Francisco, 28 November 2018 - The global preimplantation genetic testing market size is projected to amount to a value of USD 221.1 million by 2024, according to a new report by Grand View Research, Inc. The market is primarily driven by an increase in number of offspring born with inherited medical conditions. Thanks to the emergence of preimplantation genetic testing (PGT) and diagnosis to detect nearly all genetically inherited conditions, couples who are carriers of such conditions can screen their embryos at an earlier stage.
Rising adoption of IVF, resulting from an increase in incidence of pregnancy-related complications, is projected to boost demand for preimplantation genetic testing services. Women undergoing IVF are expected to undergo PGT cycles in order to prevent the transfer of chromosomal abnormalities to their offspring. Increasing demand for these tests can also be attributed to rising infertility rate around the world. This has been brought on by various environmental and lifestyle factors, eventually driving the need for PGT services. To request a sample copy or view summary of this report: www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market Further key findings from the study suggest:
Type Outlook (Market Revenue in USD Million, 2013 - 2024)
www.grandviewresearch.com/press-release/global-preimplantation-genetic-testing-pgt-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. For More Info: www.grandviewresearch.com
0 Comments
Leave a Reply. |